



Neuland Laboratories Limited

Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081

Fax: 040 30211602

Email: neuland@neulandlabs.com

www.neulandlabs.com

May 23, 2020

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Audited Financial Results for the quarter and year ended March 31, 2020, published in Financial Express and Andhra Prabha on May 23, 2020 for your reference.

Thanking you,

Yours faithfully,

For Neuland Laboratories Limited

Sarada Bhamidipati
Company Secretary

Encl: As above

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034

EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2020

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.03.2020	Quarter Ended 31.03.2019	Year Ended 31.03.2020	Year Ended 31.03.2019
1	Revenue from operations	19,164.19	17,266.17	76,271.08	66,682.95
2	Net profit for the period before tax	1,719.80	817.64	5,292.25	2,033.73
3	Net profit for the period after tax	(929.57)	663.65	1,621.05	1,644.16
4	Total comprehensive income for the period	(894.50)	611.00	1,577.65	1,675.93
5	Paid-up Equity Share Capital (Face value-₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	69,621.83 As at 31.03.2020	68,556.84 As at 31.03.2019	69,621.83 As at 31.03.2020	68,556.84 As at 31.03.2019
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic	(7.25)	5.17	12.63	13.06
	(b) Diluted	(7.25)	5.17	12.63	13.06

Note 1: The financial results for the quarter and year ended 31 March 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 22 May 2020.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 31.03.2020	Quarter Ended 31.03.2013	Year Ended 31.03.2020	Year Ended 31.03.2019
Revenue from operations	19,186.59	17,266.17	76,271.08	66,682.95
Net profit for the period before tax	1,707.68	809.05	5,249.58	1,983.50
Net profit for the period after tax	(935.00)	672.95	1,588.01	1,614.34

Note 3: The above is an extract of the detailed format of Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited

Sd/-

Dr. D.R.Rao

Chairman & Managing Director
(DIN 00107737)Place: Hyderabad
Date : 22 May 2020

శనివారం 23 మే 2020

**NEULAND LABORATORIES LIMITED**

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034

EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2020

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.03.2020	Quarter Ended 31.03.2019	Year Ended 31.03.2020	Year Ended 31.03.2019
1	Revenue from operations	19,164.19	17,266.17	76,271.08	66,682.95
2	Net profit for the period before tax	1,719.80	817.64	5,292.25	2,033.73
3	Net profit for the period after tax	(929.57)	663.65	1,621.05	1,644.16
4	Total comprehensive income for the period	(894.50)	611.00	1,577.65	1,675.93
5	Paid-up Equity Share Capital (Face value-₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	69,621.83 As at 31.03.2020	68,556.84 As at 31.03.2019	69,621.83 As at 31.03.2020	68,556.84 As at 31.03.2019
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic	(7.25)	5.17	12.63	13.06
	(b) Diluted	(7.25)	5.17	12.63	13.06

Note 1: The financial results for the quarter and year ended 31 March 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 22 May 2020.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 31.03.2020	Quarter Ended 31.03.2013	Year Ended 31.03.2020	Year Ended 31.03.2019
Revenue from operations	19,186.59	17,266.17	76,271.08	66,682.95
Net profit for the period before tax	1,707.68	809.05	5,249.58	1,983.50
Net profit for the period after tax	(935.00)	672.95	1,588.01	1,614.34

Note 3: The above is an extract of the detailed format of Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited

Sd/-

Dr. D.R.Rao

Chairman & Managing Director
(DIN 00107737)Place: Hyderabad
Date : 22 May 2020